This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q4.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.
Chemed (CHE) Q4 Earnings Miss Estimates, 2021 Outlook Dull
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2020 revenues increased 2.1% year over year to $533.3 million.
Fresenius Medical (FMS) Q4 Earnings Beat, Revenues Miss
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strength in Health Care Products segment, and performance across EMEA and Asia Pacific.
Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Medtronic (MDT) procedure volumes hurt by resurgence of COVID-19 cases despite increased demand for related diagnostics and therapies.
Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.
Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp
by Zacks Equity Research
Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
Avanos Medical (AVNS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the fourth quarter.
AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from the Nurse and Allied Solutions segment in the fourth quarter.
Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.
OPKO Health (OPK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.
Repro Med Systems (KRMD) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Repro Med Systems (KRMD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) revenues increased 4.6% year over year to $627.5 million but declined 0.4% organically in fourth-quarter fiscal 2020.
Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag
by Zacks Equity Research
Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
DaVita's (DVA) bottomline in Q4 declines year over year.
DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.
Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Hill-Rom's (HRC) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Hill-Rom's (HRC) first-quarter fiscal 2021 revenue climbed 8.2% year over year to $741.1 million.
Why Is AngioDynamics (ANGO) Up 8.7% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.